Search

Displaying results 3801 - 3810 of 7284 in total
  1. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    The FDA has approved naltrexone for the treatment of alcohol dependence. … It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction.

  2. Drug

    Tasurgratinib

    go.drugbank.com/drugs/DB21222
    Investigational

    Tasurgratinib has a monoisotopic molecular weight of 587.27 Da. … Tasurgratinib is a small molecule drug. The usage of the INN stem '-gratinib' in the name indicates that Tasurgratinib is a fibroblast growth factor receptor (FGFR) inhibitor.

  3. Drug

    Acellular nerve allograft

    go.drugbank.com/drugs/DB30293
    ApprovedInvestigational

    Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral

  4. Drug

    Anidulafungin

    go.drugbank.com/drugs/DB00362
    Approved

    There is preliminary evidence that it has a similar safety profile to caspofungin. … Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366.

    Products: GIXOFU 100 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE
  5. Drug

    Cefpodoxime

    go.drugbank.com/drugs/DB01416
    ApprovedInvestigationalVet approved

    Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.

    Products: CEFPODOXIM 1A PHAR40MG/5ML, CEFPODOXIM 1A PHARMA 100MG
  6. Drug

    Raltegravir

    go.drugbank.com/drugs/DB06817
    ApprovedInvestigational

    Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

  7. Drug

    Plecanatide

    go.drugbank.com/drugs/DB13170
    ApprovedInvestigational

    Plecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).

  8. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    in the NS5A protein and previous treatment failure with [ribavirin], [peginterferon alfa-2a], [peginterferon alfa-2b], or other NS3/4A inhibitors like [boceprevir], [simeprevir], or [telaprevir]. … [L10253] Elbasvir and [grazoprevir] are used with or without [ribavirin] with the intent to cure, or achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97%

  9. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    +7) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN) Score were observed. … It was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis.

  10. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. … neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.